

Aptus Pharma Limited

Connecting.....Life

www.aplus-pharma.com | info@apluspharma.com | export@apluspharma.com | +91 76004 27827

Date: 01/11/2025

To,
The DY. Manager,
Corporate Relationship Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001.
Scrip Code: 544529
ISIN: INE15XJ01010

Subject: Intimation of Board Meeting for consideration of Unaudited Financial Results for the Half Year ended on September 30, 2025 and Closure of Trading Window.

Dear Sir/Madam,


Pursuant to Regulation 29(1)(a) read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, 10th November 2025, inter alia, to consider and approve the Unaudited Financial Results of the Company for the half year ended 30th September 2025 and to take on record the Limited Review Report thereon.

Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Company's securities has been closed and shall remain closed till 48 hours after the declaration of the said financial results.

You are requested to kindly take the above information on record and disseminate the same on your website.

Thanking you,

Yours faithfully,
For Aptus Pharma Limited


Tejash Maheshchandra Hathi
Managing Director
DIN: 03151221